Amgen expects data from weight-loss drug trial later this year
Shares of Amgen Inc. rallied more than 11% in the extended session Thursday after the drugmaker posted adjusted earnings above expectations and said that plans for further trials for its weight-los...
Amgen scraps experimental weight loss pill, moves forward with injection
Amgen is among several drugmakers racing to join the red-hot weight loss drug space dominated by Novo Nordisk and Eli Lilly.
Ticking Time Bombs: 3 Dow Stocks to Dump While You Still Can
Here are three prominent Dow stocks facing challenges that every investor should be aware of. Even with any business's challenges, savvy investors can identify possible openings for strategic posit...
Moody's, Booking, DraftKings, Amgen stocks in focus ahead of earnings
American stocks were mixed on Wednesday as the earnings season continued and as investors waited for the latest Federal Reserve decision. The Dow Jones rose by over 65 points while the S&P 500 and ...
Will These 5 Drug/Biotech Stocks Beat Q1 Earnings Forecast?
Let's look at five large-cap pharma/biotech companies slated to release quarterly results this week.
Sandoz reaches agreement with Amgen over patent dispute
Swiss generic and biosimilar manufacturer Sandoz said on Tuesday it had reached an agreement with U.S. drugmaker Amgen resolving all patent litigation related to its U.S. denosumab biosimilars.
AMGEN ANNOUNCES WEBCAST OF 2024 FIRST QUARTER FINANCIAL RESULTS
THOUSAND OAKS, Calif. , April 29, 2024 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that it will report its first quarter 2024 financial results on Thursday, May 2, 2024, after the close of ...
What's in the Cards for Amgen (AMGN) This Earnings Season?
Volume growth from Amgen's (AMGN) key drugs like Prolia, Repatha and Evenity, among others, is expected to have been partially offset by biosimilar/generic competition for mature drugs.
Insights Into Amgen (AMGN) Q1: Wall Street Projections for Key Metrics
Get a deeper insight into the potential performance of Amgen (AMGN) for the quarter ended March 2024 by going beyond Wall Street's top -and-bottom-line estimates and examining the estimates for som...
FTC looking to accelerate inquiry into prescription-drug middlemen, chair says
The Federal Trade Commission is working to accelerate its inquiry into the prescription-drug middlemen known as pharmacy-benefit managers, while also expanding its scrutiny of drug patents that can...
Goldman Sachs Has 6 Dividend Blue Chips on Its Conviction List of Top Stocks
Sponsored: Find a Qualified Financial Advisor Finding a qualified financial advisor doesn't have to be hard.
The Dividend Goldmine: 3 Shining Stocks With Growing Payouts
There is always a constant search for dependable prospects that offer stability and advancement. In the middle of this hunt, dividend stocks with growth stand out as possible bright spots that give...
This biotech high-dividend stock is beating S&P 500
Dividend investing can be a profitable strategy for traders, providing an extra source of income alongside potential stock gains. Amgen (NASDAQ: AMGN) has demonstrated strong performance, surpassin...
Got $5,000? Here Are 3 Undervalued Stocks to Buy and Hold Forever
Delta Air Lines shares could finally take off this year once enough investors can shake off unmerited worries. Drugmaker Amgen's singles and doubles approach to the business makes more sense than a...
Big pharma is looking to fatten profits with buyouts of weight-loss drug companies. Here are 4 candidates.
A couple of big-picture trends in biotech could add up to a nice investment opportunity. First, corporate buyouts are back in style.
Related Companies